Status | Study |
Recruiting |
Study Name: Treatment Development of Triheptanoin (G1D) Condition: Epilepsy GLUT1DS1 Date: 2017-01-31 Interventions: Drug: Triheptanoin Triheptanoin will be administered for 7 days 4 times daily. |
Enrolling by invitation |
Study Name: Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome Condition: Glucose Transporter 1 Deficiency Syndrome Date: 2016-11-16 Interventions: Drug: Triheptanoin A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive |
Recruiting |
Study Name: Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) Condition: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) Date: 2016-11-07 Interventions: Drug: UX007 UX007 is a liquid |
Completed |
Study Name: Evaluation of Keyo in Children With Epilepsy Condition: Intractable Epilepsy Glucose Transporter Type 1 Deficiency Syndrome Date: 2016-09-19 Interventions: Dietary Supplement: Keyo Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in t |
Enrolling by invitation |
Study Name: Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects With Glucose Type 1 DS Condition: Glucose Transporter Type 1 Deficiency Syndrome Date: 2015-11-03 Interventions: Drug: UX007 UX007 is a liquid intended for oral (PO) administration. |
Recruiting |
Study Name: An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome Condition: Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) Date: 2014-01-13 Interventions: Drug: Triheptanoin Schedule A: Subjects previously treated |
Not yet recruiting |
Study Name: Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) Condition: Glucose Transporter Type 1 Deficiency Syndrome Date: 2013-12-12 Interventions: Drug: Triheptanoin Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride. |
Not yet recruiting |
Study Name: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) Condition: Glucose Transporter Type 1 Deficiency Syndrome Date: 2013-12-11 Interventions: Drug: Triheptanoin Triheptanoin is a 7-carbon medium chain triglyceride |
Available |
Study Name: Post Study Continuation of C7 for G1D Condition: Glut1 Deficiency Syndrome Glucose Transpo Date: 2013-12-11 Interventions: Drug: Triheptanoin Other Names: C7 oil Heptanoate hep |
Recruiting |
Study Name: The Glucose Transporter Type I Deficiency (G1D) Registry Condition: GLUT1 Deficiency Syndrome Glucose Transpo Date: 2013-12-11 Interventions: Other: No intervention This is an observational registry. No interventions are required or provided. |